<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157703</url>
  </required_header>
  <id_info>
    <org_study_id>CT2001</org_study_id>
    <nct_id>NCT00157703</nct_id>
  </id_info>
  <brief_title>G207 Followed by Radiation Therapy in Malignant Glioma</brief_title>
  <official_title>A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>MediGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single site study to evaluate the safety and tolerability of&#xD;
      intratumoral administration of G207 followed by treatment with radiation therapy in patients&#xD;
      with recurrent/progressive malignant glioma.&#xD;
&#xD;
      This study is a two stage phase 1 study, in which a de-escalating dosing scheme will be used,&#xD;
      i.e. the first patients will receive the higher dose and if excessive toxicity occurs, the&#xD;
      dose will be reduced for the following patients. The purpose of the dose de-escalation phase&#xD;
      is to find the best safe dose of G207.&#xD;
&#xD;
      In the first stage of the study, treatment with G207 will be followed by focal radiation&#xD;
      therapy on the following day, and in the second stage treatment with G207 will be followed by&#xD;
      gamma knife surgery also on the following day.&#xD;
&#xD;
      All patients will return to the clinic 28 days and 3, 6, 9 and 12 months after G207&#xD;
      administration at which time clinical assessments will be performed, and will be followed for&#xD;
      safety and survival at clinic visits or by telephone every 3 months for up to 2 additional&#xD;
      years and annually thereafter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from 1st dose to end of study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic response</measure>
    <time_frame>Withdrawal or death of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance scale</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Withdrawal or death of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of G207 in blood and saliva</measure>
    <time_frame>Last patient out</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Malignant Glioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G207</intervention_name>
    <description>1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically proven residual/recurrent glioblastoma multiforme, gliosarcoma or&#xD;
             anaplastic astrocytoma which is progressive despite radiotherapy or chemotherapy&#xD;
&#xD;
          2. Failed external beam radiotherapy &gt; 5,000 CGy at least 4 weeks prior to enrollment&#xD;
&#xD;
          3. Residual/recurrent lesion must be ≥ 1.0 cm and (for Stage 2 only) ≤ 4 cm in diameter&#xD;
             as determined by magnetic resonance imaging (MRI)&#xD;
&#xD;
          4. Normal hematological, renal and liver function&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1500/mm3&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
               -  Prothrombin time (PT) or partial thromboplastin time (PTT) &lt; 1.3 x control&#xD;
&#xD;
               -  Creatinine &lt; 1.7 mg/dl&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 mg/dl&#xD;
&#xD;
               -  Transaminases &lt; 4 times above the upper limits of the institutional norm&#xD;
&#xD;
          5. Karnofsky Performance Status score ≥ 70&#xD;
&#xD;
          6. Age &gt; 19 years-old&#xD;
&#xD;
          7. Capable of giving informed consent&#xD;
&#xD;
          8. Must be willing to practice an effective barrier method of birth control for 2 months&#xD;
             post G207 inoculation, whether male or female&#xD;
&#xD;
          9. Females of childbearing potential: negative pregnancy test within 24 hours prior to&#xD;
             G207 administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Surgical resection within 4 weeks of enrolment&#xD;
&#xD;
          2. Acute infection, granulocytopenia or medical condition precluding surgery&#xD;
&#xD;
          3. Pregnant or lactating females&#xD;
&#xD;
          4. History of encephalitis, multiple sclerosis, or other central nervous system (CNS)&#xD;
             infection&#xD;
&#xD;
          5. Tumor involvement which would require ventricular, brainstem, basal ganglia, or&#xD;
             posterior fossa inoculation or would require access through a ventricle in order to&#xD;
             deliver treatment or tumor involving both hemispheres or with subependymal/cerebral&#xD;
             spinal fluid (CSF) dissemination&#xD;
&#xD;
          6. Tumor position that could, in the Investigator's opinion, pose the risk of penetration&#xD;
             of the cerebral ventricular system during inoculation with the study drug (Note: If&#xD;
             penetration of the ventricular system is suspected or confirmed, G207 administration&#xD;
             must be aborted.)&#xD;
&#xD;
          7. Tumor locations that would expose the patient to unacceptable risk with radiation&#xD;
             therapy&#xD;
&#xD;
          8. Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or&#xD;
             herpesvirus protocol)&#xD;
&#xD;
          9. Prior participant in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy&#xD;
             protocol within 6 weeks of enrolment&#xD;
&#xD;
         10. Required steroid increase within 2 weeks prior to injection&#xD;
&#xD;
         11. HIV seropositive&#xD;
&#xD;
         12. Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir,&#xD;
             valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir)&#xD;
&#xD;
         13. Active oral or genital herpes lesion&#xD;
&#xD;
         14. Any contraindication for undergoing MRI such as pacemakers, infusion pumps,&#xD;
             ferromagnetic aneurysm clips, metal prostheses, etc.&#xD;
&#xD;
         15. Radiation treatment volume of greater than 4 cm maximum diameter (Stage 2 only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Mescheder, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medigene AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>December 12, 2008</last_update_submitted>
  <last_update_submitted_qc>December 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alice Chen</name_title>
    <organization>MediGene</organization>
  </responsible_party>
  <keyword>Malignant glioma</keyword>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>GBM</keyword>
  <keyword>Gliosarcoma</keyword>
  <keyword>Anaplastic astrocytoma</keyword>
  <keyword>Brain cancer</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Glioma</keyword>
  <keyword>recurrent/progressive malignant glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

